Strides Pharma Science Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Technical Trend Overview

Recent technical assessments indicate that Strides Pharma Science Ltd’s momentum has softened. The overall technical trend has transitioned from mildly bullish to sideways, signalling a pause in upward price momentum. This shift is corroborated by several key indicators across different timeframes, suggesting a cautious outlook for the near term.

The Moving Average Convergence Divergence (MACD) indicator, a widely used momentum oscillator, shows a mildly bearish signal on both weekly and monthly charts. This suggests that the stock’s upward momentum is weakening, with the MACD line likely crossing below the signal line, a classic bearish sign. Meanwhile, the Relative Strength Index (RSI) presents a mixed scenario: no significant signal on the weekly chart but a bearish reading on the monthly timeframe, indicating that the stock may be losing strength over a longer horizon.

Moving Averages and Bollinger Bands

On a daily basis, moving averages remain mildly bullish, implying that short-term price action still favours buyers. However, this is tempered by the Bollinger Bands analysis, which shows a mildly bearish stance on the weekly chart but a mildly bullish signal on the monthly chart. This divergence suggests that while short-term volatility may be contracting with some downside risk, the longer-term trend retains some positive bias.

Such mixed signals from Bollinger Bands often indicate consolidation phases where price oscillates within a range, awaiting a decisive breakout or breakdown. Investors should monitor the bands’ width and price position relative to the bands for clues on impending volatility shifts.

Additional Technical Indicators

The Know Sure Thing (KST) indicator, which aggregates multiple rate-of-change measures, aligns with the MACD’s bearish tone, showing mildly bearish signals on both weekly and monthly charts. This reinforces the view of waning momentum. The Dow Theory, a classical trend analysis method, currently registers no clear trend on either weekly or monthly timeframes, further emphasising the sideways movement.

On-Balance Volume (OBV), a volume-based indicator that helps confirm price trends, is mildly bearish on the weekly chart but neutral on the monthly chart. This suggests that recent trading volumes have not strongly supported price advances, adding to the cautious technical outlook.

Price and Volatility Context

Strides Pharma’s current price stands at ₹868.00, marginally down from the previous close of ₹869.05. The stock traded within a narrow intraday range, hitting a high of ₹874.00 and a low of ₹862.55, reflecting limited volatility on the day. The 52-week high remains at ₹1,024.90, while the 52-week low is ₹551.00, indicating a substantial range of price movement over the past year.

Such a wide price band underscores the stock’s potential for significant swings, but the current sideways technical trend suggests a period of consolidation before the next directional move.

Performance Relative to Sensex

Examining Strides Pharma’s returns relative to the benchmark Sensex index reveals a mixed but generally favourable long-term performance. Over the past week, the stock outperformed the Sensex with a 1.24% gain versus the index’s 0.23%. Similarly, over one month, Strides Pharma returned 0.90%, slightly ahead of the Sensex’s 0.77%.

However, year-to-date (YTD) figures show a decline of 3.81% for the stock, underperforming the Sensex’s 2.82% drop. This short-term weakness aligns with the technical indicators signalling a sideways to mildly bearish momentum.

Longer-term returns paint a more robust picture. Over one year, Strides Pharma surged 36.93%, significantly outpacing the Sensex’s 9.35% gain. The three-year return is particularly impressive at 511.68%, dwarfing the Sensex’s 36.45%. Even over five and ten years, the stock has delivered strong absolute returns of 108.68% and 93.71%, respectively, though the ten-year figure trails the Sensex’s 249.29%.

Mojo Score and Rating Update

MarketsMOJO’s latest assessment assigns Strides Pharma a Mojo Score of 48.0, reflecting a cautious stance. The Mojo Grade has been downgraded from Hold to Sell as of 16 Feb 2026, signalling a deterioration in the stock’s technical and fundamental outlook. The Market Cap Grade stands at 3, indicating a mid-tier capitalisation relative to peers.

This downgrade is consistent with the mixed technical signals and the recent momentum shift, suggesting investors should exercise prudence and closely monitor developments before committing fresh capital.

Implications for Investors

The current technical landscape for Strides Pharma Science Ltd suggests a period of consolidation with a risk of further downside if bearish indicators intensify. The mildly bearish MACD and KST on weekly and monthly charts, combined with a bearish monthly RSI, point to weakening momentum that could challenge short-term bullishness indicated by daily moving averages.

Investors should watch for confirmation signals such as a sustained break below key moving averages or a widening of Bollinger Bands to the downside, which could herald a more pronounced correction. Conversely, a rebound in volume-supported price advances and improvement in momentum oscillators could restore confidence and resume the longer-term uptrend.

Conclusion

Strides Pharma Science Ltd’s recent technical parameter changes highlight a nuanced momentum shift from mildly bullish to sideways, underscored by mixed signals from key indicators such as MACD, RSI, Bollinger Bands, and moving averages. While the stock’s long-term performance remains strong relative to the Sensex, short-term caution is warranted given the downgrade to a Sell rating and the presence of bearish technical cues.

Investors should maintain a vigilant approach, balancing the stock’s historical strength against emerging signs of momentum deterioration. Monitoring volume trends, price action around moving averages, and momentum oscillators will be critical in anticipating the stock’s next directional move within the Pharmaceuticals & Biotechnology sector.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today